{
    "id": 25953,
    "fullName": "PIM2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PIM2 positive indicates the presence of the PIM2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 11040,
        "geneSymbol": "PIM2",
        "terms": [
            "PIM2"
        ]
    },
    "variant": "positive",
    "createDate": "01/19/2017",
    "updateDate": "01/08/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9787,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of LGH447, Velcade (bortezomib), and Adexone (dexamethasone) resulted in a strong synergistic effect in myeloma cells expressing PIM2, demonstrating decreased cell viability (PMID: 27440267).",
            "molecularProfile": {
                "id": 27092,
                "profileName": "PIM2 positive"
            },
            "therapy": {
                "id": 5231,
                "therapyName": "Bortezomib + Dexamethasone + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 70004,
                "name": "myeloid neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7604,
                    "pubMedId": 27440267,
                    "title": "The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27440267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9788,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of LGH447, Revlimid (lenalidomide), and Adexone (dexamethasone) resulted in a strong synergistic effect in myeloma cells expressing PIM2, demonstrating decreased cell viability (PMID: 27440267).",
            "molecularProfile": {
                "id": 27092,
                "profileName": "PIM2 positive"
            },
            "therapy": {
                "id": 5232,
                "therapyName": "Dexamethasone + Lenalidomide + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 70004,
                "name": "myeloid neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7604,
                    "pubMedId": 27440267,
                    "title": "The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27440267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9789,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of LGH447, Pomalyst (pomalidomide), and Adexone (dexamethasone) resulted in a strong synergistic effect in myeloma cells expressing PIM2, demonstrating decreased cell viability (PMID: 27440267).",
            "molecularProfile": {
                "id": 27092,
                "profileName": "PIM2 positive"
            },
            "therapy": {
                "id": 5233,
                "therapyName": "Dexamethasone + LGH447 + Pomalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 70004,
                "name": "myeloid neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7604,
                    "pubMedId": 27440267,
                    "title": "The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27440267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9790,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of LGH447 and Adexone (dexamethasone) resulted in a synergistic effect in myeloma cells expressing PIM2, demonstrating decreased cell viability (PMID: 27440267).",
            "molecularProfile": {
                "id": 27092,
                "profileName": "PIM2 positive"
            },
            "therapy": {
                "id": 5234,
                "therapyName": "Dexamethasone + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 70004,
                "name": "myeloid neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7604,
                    "pubMedId": 27440267,
                    "title": "The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27440267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9786,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, myeloma cell lines expressing PIM2 demonstrated sensitivity to LGH447, resulting in cell cycle disruption and apoptotic induction in culture and decreased tumor burden in xenograft models (PMID: 27440267).",
            "molecularProfile": {
                "id": 27092,
                "profileName": "PIM2 positive"
            },
            "therapy": {
                "id": 2402,
                "therapyName": "LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 70004,
                "name": "myeloid neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7604,
                    "pubMedId": 27440267,
                    "title": "The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27440267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27092,
            "profileName": "PIM2 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}